Application of MIDD in Clinical Research of Antitumor Drugs

• Published in: Zhongguo fei ai za zhi Vol. 25; no. 7; pp. 487 - 492
• Main Authors: Yu, Mengyang, Wang, Hongyun
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 20.07.2022; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Drug Development; exposure-response relationship; Humans; Lung Neoplasms; model-informed drug development; osimertinib; pembrolizumab; population pharmacokinetics; Population pharmacokinetics; Osimertinib; Pembrolizumab; Model-informed drug development; Exposure-response relationship
• ISSN: 1009-3419; 1999-6187; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2022.101.38

The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to provide references for the application of MIDD to guide the clinical research of antitumor drugs.
.